The US regulator is to review a submission from British drugmaker AstraZeneca (LSE: AZN) for capivasertib, in combination with Faslodex (fulvestrant), under the Priority Review scheme.
The novel AKT inhibitor, which is backed by positive results from the Phase III CAPItello-291 study, has the potential to become a new treatment for people with breast cancer who have progressed despite existing options, or who have become resistant to them.
When added to Faslodex, capivasertib demonstrated a 40% reduction in the risk of disease progression or death in the overall trial population.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze